| Journal | JMIR research protocols |
| Study Type | Cohort |
| Population | Human participants |
The SMILE study addresses a critical knowledge gap in cannabis medicine—the lack of rigorous longitudinal data on real-world medical marijuana use in older adults, our fastest-growing patient demographic. This protocol establishes a framework for generating the evidence-based outcomes data we desperately need to guide clinical decision-making in geriatric cannabis care.
SMILE is a prospective cohort study protocol designed to track older adult medical marijuana users longitudinally, examining both short-term and long-term effects on pain, cognitive function, physical and mental health, and quality of life. The study aims to identify specific product characteristics and patient subgroups associated with therapeutic benefits versus adverse effects. While this publication presents only the study protocol rather than results, it represents a significant methodological advancement in cannabis research by focusing on real-world product use rather than standardized formulations in controlled settings. The longitudinal design will help address the current evidence gap in geriatric cannabis medicine, though actual clinical insights await study completion.
“I’ve been waiting for exactly this type of rigorous, real-world evidence to emerge from the research community. While we won’t see results for years, this protocol gives me confidence that we’re finally moving beyond anecdotal reports toward the systematic data older patients and their families deserve.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- Why is medical marijuana research specifically important for older adults?
- What are the main health outcomes being studied in older adults using medical marijuana?
- Is chronic pain the primary reason older adults use medical marijuana?
- What makes this study design clinically valuable for healthcare providers?
- How will this research impact clinical practice and policy for medical marijuana in older adults?
FAQ
Why is medical marijuana research specifically important for older adults?
Older adults represent the fastest-growing group of medical marijuana users in the United States, yet scientific evidence remains limited regarding its effects on this population. This demographic gap is particularly concerning given that older adults may have different physiological responses and are at higher risk for drug interactions and adverse effects.
What are the main health outcomes being studied in older adults using medical marijuana?
The SMILE study will examine both short- and long-term effects on pain management, cognitive function, physical and mental health, and overall quality of life. The research aims to identify which specific medical marijuana products and patient characteristics are associated with improved outcomes versus side effects.
Is chronic pain the primary reason older adults use medical marijuana?
Yes, according to this research protocol, chronic pain is identified as the most common reason older adults seek medical marijuana treatment. This aligns with the high prevalence of chronic pain conditions in geriatric populations and the challenges of managing pain with traditional pharmaceuticals in this age group.
What makes this study design clinically valuable for healthcare providers?
The SMILE study employs a prospective cohort design that will track real-world medical marijuana use over time, providing more clinically relevant data than controlled trials. This approach will help identify which specific products and patient subgroups experience the best outcomes, informing evidence-based prescribing decisions.
How will this research impact clinical practice and policy for medical marijuana in older adults?
The study aims to provide rigorous longitudinal data to better inform both clinical practice and public policy regarding medical marijuana use in older adults. Given the current limited evidence base, these findings could significantly influence treatment guidelines and regulatory decisions for this rapidly growing patient population.